There is one clinical trial.
This study is designed rapidly assess safety and preliminary efficacy in hospitalized patients with COVID-19 respiratory distress to provide clinical guidance for possible wider use in treating patients in this pandemic environment. This data will be used for FDA IND filings and pursuit of a BLA.
Description: Frequency of all reported adverse events in studyMeasure: Frequency of all adverse events Time: Through study completion, an average of three months
Description: Frequency of SAEs in the 6 hours post-infusion for each infusionMeasure: Frequency of infusion related serious adverse events Time: 6 hours post infusion
Description: Frequency of all serious adverse events in studyMeasure: Frequency of serious adverse events Time: Through study completion, an average of three months
Description: All-cause mortality through Day 28Measure: Mortality Time: Study days 0-28
Description: Ventilator free days through Study day 28Measure: Ventilator Free Days Time: Study days 0-28
Description: Total days not in ICU from Study day 0 through Study day 28Measure: ICU Free Days Time: Days 0 through 28
Description: Total Days in Hospital from Day 0 through discharge for survivorsMeasure: Total Hospital Days Time: Days 0 through discharge, an average of 28 days
Description: Total Days in ICU from Day 0 through discharge for survivorsMeasure: Total ICU Days Time: Days 0 through discharge, an average of 28 days
Description: Improvement in oxygenation comparing Study day 0, to days 2, 4, 6Measure: Improvement in Oxygenation Time: Study days 0, 2, 4, 6
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports